SCOPUS 정보 검색 플랫폼

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1647-1649

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

(6) Daelman, L a,b Maitrot, A a Maarouf, A a Chaunu, M P a Papeix, C c Tourbah, A a,b

a REIMS UNIVERSITY HOSPITAL (France)

b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE (France)

c GHPS (France)

Author keywords

fingolimod; MRI; Multiple sclerosis; natalizumab; relapsing remitting

Indexed keywords

FINGOLIMOD; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ANALOGS AND DERIVATIVES; ASTHENIA; CASE REPORT; COMPLICATION; DISEASE COURSE; DRUG ADMINISTRATION; DRUG SUBSTITUTION; EPILEPSIES, PARTIAL; EPILEPSY, TONIC-CLONIC; FEMALE; HUMAN; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHENIA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; EPILEPSIES, PARTIAL; EPILEPSY, TONIC-CLONIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868004886 PISSN: 13524585 EISSN: 14770970 Source Type: Journal
DOI: 10.1177/1352458512458009 Document Type: Article

Times cited : (46)

References (9)

1
- 61549088471
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
- Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009 ; 72: 396-401
- (2009) Neurology , vol.72 , pp. 396-401
- Stuve, O.¹ Cravens, P.D.² Frohman, E.M.³

2
- 79958137883
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
- (2011) Neurology , vol.76 , pp. 1858-1865
- O'Connor, P.W.¹ Goodman, A.² Kappos, L.³

3
- 0037413467
- A controlled trial of natalizumab for relapsing multiple sclerosis
- DOI 10.1056/NEJMoa020696
- Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23 (Pubitemid 36026342)
- (2003) New England Journal of Medicine , vol.348 , Issue.1 , pp. 15-23
- Miller, D.H.¹ Khan, O.A.² Sheremata, W.A.³ Blumhardt, L.D.⁴ Rice, G.P.A.⁵ Libonati, M.A.⁶ Willmer-Hulme, A.J.⁷ Dalton, C.M.⁸ Miszkiel, K.A.⁹ O'Connor, P.W.¹⁰

4
- 77956377928
- Considerations on discontinuing natalizumab for the treatment of multiple sclerosis
- Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol. 2010 ; 68: 409-411
- (2010) Ann Neurol , vol.68 , pp. 409-411
- Berger, J.R.¹ Centonze, D.² Comi, G.³

5
- 79951543155
- Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy
- Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 ; 68: 186-191
- (2011) Arch Neurol , vol.68 , pp. 186-191
- Miravalle, A.¹ Jensen, R.² Kinkel, R.P.³

6
- 41549130359
- Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients
- DOI 10.1212/01.wnl.0000265393.03231.e5, PII 0000611420080325100002
- Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patient. Neurology. 2008 ; 70: 1150-1151 (Pubitemid 351464749)
- (2008) Neurology , vol.70 , Issue.13 PART 2 , pp. 1150-1151
- Vellinga, M.M.¹ Castelijns, J.A.² Barkhof, F.³ Uitdehaag, B.M.J.⁴ Polman, C.H.⁵

7
- 79958125165
- Interruption of natalizumab therapy for multiple sclerosis: What are the risks?
- Naismith RT, Bourdette D. Interruption of natalizumab therapy for multiple sclerosis: What are the risks?. Neurology. 2011 ; 76: 1854-1855
- (2011) Neurology , vol.76 , pp. 1854-1855
- Naismith, R.T.¹ Bourdette, D.²

8
- 84862908479
- Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
- Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 ; 18: 113-115
- (2012) Mult Scler , vol.18 , pp. 113-115
- Min, J.H.¹ Kim, B.J.² Lee, K.H.³

9
- 84860344893
- Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?
- Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?. Neurology. 2012 ; 78: 928-930
- (2012) Neurology , vol.78 , pp. 928-930
- Castrop, F.¹ Kowarik, M.C.² Albrecht, H.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.